trending Market Intelligence /marketintelligence/en/news-insights/trending/CCa7sLl4SQF4t4gtWgULQg2 content esgSubNav
In This List

Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


Luminex completes acquisition of Merck KGaA's cell analysis unit in $75M deal

Luminex Corp. has completed the acquisition of Merck KGaA's cell analysis equipment provider MilliporeSigma in a $75 million cash, stock and asset deal.

The acquisition expands the Austin, Texas-based company's footprint in life science research and broadens its existing offering of flow-based detection systems. The portfolio includes flow cytometry products sold under the brand names Amnis, for cell-based analysis, and Guava, which are high-performance systems based on microcapillary technologies.

Luminex expects the acquisition to contribute $40 million to $50 million toward its 2019 revenues.

Cantor Fitzgerald & Co. acted as financial adviser and Smith Gambrell & Russell LLP served as legal counsel to Luminex.